Dr. Coleman completed his Obstetrics & Gynecology residency at Northwestern University Medical Center in Chicago, Illinois, and completed his fellowship at The University of Texas MD Anderson Cancer Center in 1993. From 1993-1996, he served as Assistant Professor at Creighton University followed by service as Vice-Chairman, Department of Obstetrics and Gynecology at the University of Texas, Southwestern Medical Center. Dr. Coleman joined as Faculty at MD Anderson Cancer center in 2004 and served as Professor and Executive Director for Cancer Network Research, holding the Ann Rife Cox Chair in Gynecology. In March 2020, he joined US Oncology Research (USOR) as Chief Scientific Officer and served briefly as Chief Medical Officer for Sarah Cannon Research Institute (SCRI). He practices at Texas Oncology, US Oncology Network and currently serves as Chief Medical officer for Vaniam Group. He also serves as Vice President, GOG Foundation and is Special Advisor to the President for GOG Partners. Dr. Coleman has authored or coauthored over 800 scientific publications, including over 470 peer-reviewed articles, along with numerous book chapters, monographs, invited articles, and textbooks. He was the 2019 APGO-CREOG awardee for Excellence in Teaching. He served as President of SGO (2015-2016) and President of IGCS (2020-2022). He was recently inducted into MJH Life Sciences™ 2020 class of “Giants in Cancer Care®.”

Dr. Auclair is a specialist in gynecologic oncology and an assistant clinical professor at the CIUSSS de l'Est-de-l'île-de-Montréal. She obtained her MD from McGill University in Montreal in 2010, her residency in obstetrics and gynecology also at McGill University in 2016, and her subspecialty in gynecologic oncology at the Université de Montréal in 2019. Dr. Auclair completed her American Board of Obesity Medicine in 2021 and subsequently founded a survivorship clinic for patients followed by her team at Maisonneuve-Rosemont Hospital. Dr. Auclair completed her Master's degree in Healthcare Quality at QUEEN's University in Kingston in 2023. She represents her department on the Maisonneuve-Rosemont Hospital's Central Committee for the Evaluation of Medical, Dental, and Pharmaceutical Procedures. She has also contributed to scientific articles, a book chapter, and clinical guidelines, including the SOGC clinical guideline "Classification and Management of Endometrial Hyperplasia" and the joint guideline of the Canadian Society of Gynecologic Oncology (GOC), the Canadian Colposcopy Society (CCS), and the Canadian Partnership Against Cancer (CPAC) "Canadian Colposcopy Guidelines: A Risk-Based Approach to the Management and Surveillance of Cervical Dysplasia, 2023." Her clinical interests include survivorship, medical management of obesity, and early recovery.

Dr. David Fortin completed his medical and neurosurgical training at the Université de Sherbrooke. He then specialized in neuro-oncology at the University of Western Ontario for one year, then at Oregon Health & Science University (OHSU) for two years. Upon returning to the Université de Sherbrooke in 2000, he founded a research laboratory specializing in the treatment of brain tumors. It was in this context that he introduced a unique brain tumor treatment technique in Canada: intra-arterial chemotherapy with blood-brain barrier opening. Dr. Fortin is a neurosurgeon and neuro-oncologist at the CIUSSS de l’Estrie – CHUS. He also works at the CHUS Research Center in Neuroscience and Oncology. He is a full professor of surgery, radiobiology, and pharmacology in the Faculty of Medicine and Health Sciences at the Université de Sherbrooke. He has over 130 publications and 160 scientific abstracts to his credit. He lectures extensively nationally and internationally. Dr. Fortin has received numerous awards: Mérite Estrien in 2003, Person of the Year in 2002, César Galéano Award for Best Professor from the Faculty of Medicine and Health Sciences at the Université de Sherbrooke from 2005 to 2010, and the Research Achievement Award from the CHUS Clinical Research Center in 2012. In 2016, his team received the Best International Presentation Award at the prestigious Congress of Neurological Surgeons. Dr. Fortin received the 2018 Specialist of the Year Award for Quebec from the Royal College of Physicians and Surgeons of Canada. He was also one of three finalists for the Prix d'excellence du Collège des médecins du Québec in 2022.

Biography to come